Scientific Director - Publications
The Lockwood Group, LLC- Full Time
- Senior (5 to 8 years)
Employment Type: Full time
PTC Therapeutics is a global commercial biopharmaceutical company. For over 25 years, our team has been deeply committed to a unified purpose: Extending life’s moments for children and adults living with a rare disease.
At PTC, we cultivate an inclusive culture where everyone feels valued, respected, and empowered. We welcome candidates from all backgrounds to join our team, fostering a strong sense of belonging.
Visit our website to learn more about our company and culture: www.ptcbio.com
The Director, Global Scientific Publications is responsible for the management and delivery of scientific publications in alignment with brand/therapeutic area publication plans. This includes, but may not be limited to, working with internal stakeholders, vendors, and healthcare professionals to review and provide scientific consultation regarding publication-related material across all therapeutic areas. The incumbent may also develop scientific content for publications supporting the objectives of the Global Medical Affairs function.
The Director, Global Scientific Publications enhances the effectiveness of our external relationships and collaborations by managing and optimizing the publication team’s collaborations with authors, vendors, and internal stakeholders to ensure the highest quality and accuracy of our communication materials and related publication activities. The Director manages direct report(s).
The incumbent works cross-functionally with internal departments and external resources on scientific publication-related issues. The Director, Global Scientific Publications ensures adherence to relevant regulatory requirements, company Standard Operating Procedures (SOPs), and industry standards as appropriate.
Develops therapies for CNS disorders
Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.